Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options. The company has announced that its Chief Executive Officer Doug Drysdale and SVP of Clinical Operations Allison House-Gecewicz will be speaking at the Psychedelic Science 2023 Conference hosted by the … Continue reading InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Participate at Psychedelic Science 2023 Conference